MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
1.085
+0.045
+4.33%
After Hours: 1.040 -0.045 -4.15% 18:56 12/26 EST
OPEN
1.030
PREV CLOSE
1.040
HIGH
1.090
LOW
0.9300
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
1.185
52 WEEK LOW
0.3418
MARKET CAP
94.83M
P/E (TTM)
-3.5170
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IPSC last week (1215-1219)?
Weekly Report · 12/22 09:17
Century Therapeutics CEO Brent Pfeiffenberger Reports Acquisition of Common Shares
Reuters · 12/16 23:38
Weekly Report: what happened at IPSC last week (1208-1212)?
Weekly Report · 12/15 09:18
Century Therapeutics Updates on Cell Therapy Advancements
TipRanks · 12/12 21:33
Century Therapeutics Inc Files Initial Statement of Beneficial Ownership for Director Han Myung Lee
Reuters · 12/11 23:04
Century Therapeutics Expands Board with New Appointments
TipRanks · 12/09 13:28
Century Therapeutics appoints Lee, Murphy to board of directors
TipRanks · 12/09 13:10
Century Therapeutics Appoints Han Lee and Martin Murphy to Board
Reuters · 12/09 13:00
More
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.